Results 51 to 60 of about 108,375,652 (210)

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis

Frontiers in Oncology
BackgroundThe effectiveness of a dexamethasone-sparing strategy in the treatment of breast cancer with anthracycline-cyclophosphamide therapy when combined with first-generation 5-HT3 receptor antagonists (RAs) and neurokinin-1 RAs is unclear.
Daichi Watanabe, Daichi Watanabe, Hirotoshi Iihara, Hirotoshi Iihara, Hirotoshi Iihara, Ryo Kobayashi, Ryo Kobayashi, Hironori Fujii, Ryutaro Mori, Keisuke Kumada, Keisuke Kumada, Masahito Shimizu, Masahito Shimizu, Manabu Futamura, Akio Suzuki, Akio Suzuki   +15 more
doaj   +1 more source

A Novel Mechanism of Endoplasmic Reticulum Stress‐ and c‐Myc‐Degradation‐Mediated Therapeutic Benefits of Antineurokinin‐1 Receptor Drugs in Colorectal Cancer

Advanced Science, 2021
The neurokinin‐1 receptor (NK‐1R) antagonists are approved as treatment for chemotherapy‐associated nausea and vomiting in cancer patients. The emerging role of the substance P‐NK‐1R system in oncogenesis raises the possibility of repurposing well ...
Yue Shi, Xi Wang, Yueming Meng, Junjie Ma, Qiyu Zhang, Gang Shao, Lingfei Wang, Xurui Cheng, Xiangyu Hong, Yong Wang, Zhibin Yan, Yihai Cao, Jian Kang, Caiyun Fu   +13 more
doaj   +1 more source

Comparative analysis of virtual screening approaches in the search for novel EphA2 receptor antagonists [PDF]

, 2015
The EphA2 receptor and its ephrin-A1 ligand form a key cell communication system, which has been found overexpressed in many cancer types and involved in tumor growth.
PALA, Daniele, Callegari, Donatella, Scalvini, Laura, Mor, Marco, Lodola, Alessio, Donatella Callegari, Pala, Daniela, Incerti, Matteo, Rivara, Silvia, Daniele Pala, Tognolini, Massimiliano, Marco Mor, Massimiliano Tognolini, Laura Scalvini, Matteo Incerti, Silvia Rivara, Alessio Lodola   +16 more
core   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer

The Scientific World Journal, 2012
The recent years have witnessed an exponential increase in cancer research, leading to a considerable investment in the field. However, with few exceptions, this effort has not yet translated into a better overall prognosis for patients with cancer, and ...
Marisa Rosso, Miguel Muñoz, Michael Berger   +2 more
doaj   +1 more source

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

Allergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch   +9 more
wiley   +1 more source

Antitumor Strategies Targeting Peptidergic Systems

Encyclopedia
Peptidergic systems show promise as targets for fighting tumors. While some peptides encourage the growth and spread of tumor cells and angiogenic mechanisms, others display antitumor properties. As such, peptide ligands and receptor antagonists could be
Francisco D. Rodríguez, Rafael Coveñas
doaj   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting

Cancer Management and Research, 2017
Bernardo Leon Rapoport The Medical Oncology Centre of Rosebank, Johannesburg, South Africa Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens.
Rapoport BL
doaj